

*Contact Person:* Denise Wiesch, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3150, MSC 7770, Bethesda, MD 20892, (301) 435-0684, [wieschd@csr.nih.gov](mailto:wieschd@csr.nih.gov).

*Name of Committee:* Risk, Prevention and Health Behavior Integrated Review Group; Behavioral Medicine, Interventions and Outcomes Study Section.

*Date:* October 5–6, 2009.

*Time:* 8:30 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Courtyard by Marriott, 1000 Aliceanna Street, Baltimore, MD 21202.

*Contact Person:* Lee S. Mann, JD, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3186, MSC 7848, Bethesda, MD 20892, 301-435-0677, [mannl@csr.nih.gov](mailto:mannl@csr.nih.gov).

*Name of Committee:* Musculoskeletal, Oral and Skin Sciences Integrated Review Group; Arthritis, Connective Tissue and Skin Study Section.

*Date:* October 5–6, 2009.

*Time:* 8:30 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Hilton Washington/Rockville, 1750 Rockville Pike, Rockville, MD 20852.

*Contact Person:* Aftab A. Ansari, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4108, MSC 7814, Bethesda, MD 20892, (301) 594-6376, [ansaria@csr.nih.gov](mailto:ansaria@csr.nih.gov).

*Name of Committee:* Biobehavioral and Behavioral Processes Integrated Review Group; Adult Psychopathology and Disorders of Aging Study Section.

*Date:* October 5–6, 2009.

*Time:* 8:30 a.m. to 11 a.m.

*Agenda:* To review and evaluate grant applications.

*Place:* InterContinental Harbor Court Baltimore, 550 Light Street, Baltimore, MD 21202.

*Contact Person:* Estina E. Thompson, PhD, MPH, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3178, MSC 7848, Bethesda, MD 20892, 301-496-5749, [thompstone@mail.nih.gov](mailto:thompstone@mail.nih.gov).

*Name of Committee:* Brain Disorders and Clinical Neuroscience Integrated Review Group; Clinical Neuroscience and Neurodegeneration Study Section.

*Date:* October 5–6, 2009.

*Time:* 8:30 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Melrose Hotel, 2430 Pennsylvania Avenue, NW., Washington, DC 20037.

*Contact Person:* Seetha Bhagavan, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5194, MSC 7846, Bethesda, MD 20892, (301) 435-1121, [bhagavas@csr.nih.gov](mailto:bhagavas@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; SAT and BTSS Member Conflict.

*Date:* October 5, 2009.

*Time:* 2 p.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. (Telephone Conference Call)

*Contact Person:* Roberto J. Matus, MD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5108, MSC 7854, Bethesda, MD 20892, (301) 435-2204, [matusr@csr.nih.gov](mailto:matusr@csr.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: September 9, 2009.

**Jennifer Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. E9-22218 Filed 9-15-09; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Center for Complementary & Alternative Medicine; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Center for Complementary and Alternative Medicine Special Emphasis Panel. SBIR.

*Date:* October 13, 2009.

*Time:* 2 p.m. to 4 p.m.

*Agenda:* To review and evaluate grant applications and/or proposals.

*Place:* National Institutes of Health/NCCAM, 6707 Democracy Blvd, Suite 401, Bethesda, MD 20892. (Telephone Conference Call)

*Contact Person:* Ray Bramhall, PhD, Scientific Review Officer, National Center for Complementary and Alternative Medicine, 6707 Democracy Blvd., Suite 401, Bethesda, MD 20892. [bramhallr@mail.nih.gov](mailto:bramhallr@mail.nih.gov).

*Name of Committee:* National Center for Complementary and Alternative Medicine Special Emphasis Panel. Basic and Preclinical Research and Career Development Applications.

*Date:* October 19–20, 2009.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Courtyard by Marriott, Gaithersburg Washingtonian Center, 204 Boardwalk Place, Gaithersburg, MD 20878.

*Contact Person:* Peter Kozel, PhD, Scientific Review Officer, NCCAM, 6707 Democracy Boulevard, Suite 401, Bethesda, MD 20892-5475. 301-496-8004. [kozelp@mail.nih.gov](mailto:kozelp@mail.nih.gov).

*Name of Committee:* National Center for Complementary and Alternative Medicine Special Emphasis Panel. Fellowship and Training Applications.

*Date:* October 28, 2009.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* The Legacy Hotel and Meeting Center, 1775 Rockville Pike, Rockville, MD 20852.

*Contact Person:* Peter Kozel, PhD, Scientific Review Officer, NCCAM, 6707 Democracy Boulevard, Suite 401, Bethesda, MD 20892-5475. 301-496-8004. [kozelp@mail.nih.gov](mailto:kozelp@mail.nih.gov).

*Name of Committee:* National Center for Complementary and Alternative Medicine Special Emphasis Panel. Clinical Science.

*Date:* October 29–30, 2009.

*Time:* 9 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road, NW., Washington, DC 20015.

*Contact Person:* Laurie Friedman Donze, PhD, Scientific Review Officer, Office of Scientific Review, National Center for Complementary and Alternative Medicine, NIH, 6707 Democracy Blvd., Suite 401, Bethesda, MD 20892. 301-402-1030. [donzel@mail.nih.gov](mailto:donzel@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program No. 93.213, Research and Training in Complementary and Alternative Medicine, National Institutes of Health, HHS)

Dated: September 10, 2009.

**Jennifer Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. E9-22311 Filed 9-15-09; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA-2001-F-0049] (formerly Docket No. 2001F-0047)

#### National Fisheries Institute; Filing of Food Additive Petition; Amendment

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is amending the

filing notice for a food additive petition filed by the National Fisheries Institute, to provide for the safe use of ionizing radiation for control of foodborne pathogens in crustaceans and processed crustaceans.

**FOR FURTHER INFORMATION CONTACT:**

Lane A. Highbarger, Center for Food Safety and Applied Nutrition (HFS-255), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 301-436-1204.

**SUPPLEMENTARY INFORMATION:** Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), a notice was published in the **Federal Register** of February 6, 2001 (66 FR 9086) announcing that a food additive petition (FAP 1M4727) had been filed by the National Fisheries Institute, 7918 Jones Branch Dr., McLean, VA 22102, proposing that the food additive regulations in part 179 *Irradiation in the Production, Processing and Handling of Food* (21 CFR part 179) be amended to provide for the safe use of ionizing radiation for control of foodborne pathogens in raw-, frozen-, cooked-, partially cooked-, shelled-, or dried crustaceans, or cooked- or ready-to-cook crustaceans processed with batter, breading, spices, or small amounts of other food ingredients.

Subsequent to the publication of the filing notice, the National Fisheries Institute amended the scope of their petition so as to exclude the use of breading or batter. FDA received a letter from the National Fisheries Institute, dated July 16, 2009, asking FDA to modify the scope of the petition so that breading and batter are not included.

Therefore, FDA is amending the filing notice of February 6, 2001, to state that the National Fisheries Institute is proposing that the food additive regulations in part 179 be amended to provide for the use of ionizing radiation for the control of foodborne pathogens in raw-, frozen-, cooked-, partially cooked-, shelled-, or dried-crustaceans or cooked- or ready-to-cook crustaceans processed with spices or small amounts of other food ingredients.

The agency has determined under 21 CFR 25.32(i) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

Dated: September 4, 2009.

**Laura M. Tarantino,**

*Director, Office of Food Safety, Center for Food Safety and Applied Nutrition.*

[FR Doc. E9-22008 Filed 9-15-09; 8:45 am]

**BILLING CODE 4160-01-S**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

[Docket Number NIOSH-057]

**Request for Information on 1-Bromopropane**

**AGENCY:** National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice of public comment period.

**SUMMARY:** The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) intends to evaluate the scientific data on the brominated organic solvent, 1-Bromopropane (1-BP, CAS # 106-94-5, also known as n-propyl bromide), and develop appropriate communication documents, such as a Current Intelligence Bulletin, Criteria Document and/or other informational products, and establish a Recommended Exposure Limit (REL) for 1-BP. NIOSH is requesting information on the following: (1) published and unpublished reports and findings from *in vitro* and *in vivo* toxicity studies with 1-BP, (2) information on possible health effects observed in workers exposed to 1-BP, (3) information on workplaces and products in which 1-BP can be found, (4) description of work tasks and scenarios with a potential for exposure to 1-BP, (5) workplace exposure data, and (6) information on control measures (e.g., engineering controls, work practices, personal protective equipment) that are being used in workplaces where potential exposures to 1-BP occur.

**Public Comment Period:** Comments must be received by December 14, 2009.

**ADDRESSES:** You may submit comments, identified by docket number NIOSH-057, by any of the following methods:

- **Mail:** NIOSH Docket Office, Robert A. Taft Laboratories, MS-C34, 4676 Columbia Parkway, Cincinnati, OH 45226.
- **Facsimile:** (513) 533-8285.
- **E-mail:** [nioshdocket@cdc.gov](mailto:nioshdocket@cdc.gov).

All information received in response to this notice will be available for public examination and copying at the NIOSH Docket Office, 4676 Columbia Parkway, Cincinnati, Ohio 45226. A complete electronic docket containing all comments submitted will be available on the NIOSH Web page at <http://www.cdc.gov/niosh/docket>, and comments will be available in writing by request. NIOSH includes all comments received without change in the docket, including any personal information provided.

[www.cdc.gov/niosh/docket](http://www.cdc.gov/niosh/docket), and comments will be available in writing by request. NIOSH includes all comments received without change in the docket, including any personal information provided.

**FOR FURTHER INFORMATION CONTACT:** G. Scott Dotson, PhD, NIOSH, Robert A Taft Laboratories, MS-C32, 4676 Columbia Parkway, Cincinnati, OH 45226, telephone (513) 533-8540.

**SUPPLEMENTARY INFORMATION:** 1-BP is a brominated organic solvent that has received increased global attention in recent years as a potential alternative for ozone depleting substances and other compounds with known adverse health effects, such as chlorofluorocarbons (CFC), hydrochlorofluorocarbons (HCFC), and methylene chloroform. 1-BP is used in multiple industrial processes including vapor and immersion degreasing operations, and as a solvent in industries using aerosol-applied adhesives; 1-BP is also proposed as a replacement solvent for perchloroethylene in the dry-cleaning sector. The National Toxicology Program (NTP) estimated that approximately 8.2 million pounds (lbs) of 1-BP were used in the United States (U.S.) in 2002. Estimates of the number of workers exposed to 1-BP are unavailable due to limited exposure data and its relatively recent introduction into domestic commerce.

The toxic nature of 1-BP is not fully understood. Recently published case reports describe possible adverse health effects, including neurotoxicity, following occupational exposures to 1-BP. The findings of animal toxicity studies in rats and mice indicate that 1-BP may be a reproductive and developmental toxicant, in addition a neurotoxicant. No occupational exposure limits for 1-BP have been established by NIOSH or the Occupational Safety and Health Administration (OSHA).

NIOSH seeks to obtain materials, including published and unpublished reports and research findings, to evaluate the possible health risks of occupational exposure to 1-BP. Examples of requested information include, but are not limited to, the following:

(1) Identification of industries or occupations in which exposures to 1-BP may occur.

(2) Trends in the production and use of 1-BP and 1-BP containing compounds.

(3) Description of work tasks and scenarios with a potential for exposure to 1-BP.